Raptor Pharmaceutical Corp. (RPTP) : Atika Capital Management added new position in Raptor Pharmaceutical Corp. during the most recent quarter end. The investment management firm now holds 1,358,000 shares of Raptor Pharmaceutical Corp. which is valued at $9,207,240 , the company said in a statement filed on Aug 15, 2016 with the SEC.Raptor Pharmaceutical Corp. makes up approximately 4.59% of Atika Capital Management’s portfolio.
Other Hedge Funds, Including , Voya Investment Management boosted its stake in RPTP in the latest quarter, The investment management firm added 4,137 additional shares and now holds a total of 38,504 shares of Raptor Pharmaceutical Corp. which is valued at $261,057.Tfs Capital reduced its stake in RPTP by selling 324,164 shares or 70.54% in the most recent quarter. The Hedge Fund company now holds 135,382 shares of RPTP which is valued at $917,890. Raptor Pharmaceutical Corp. makes up approx 0.16% of Tfs Capital’s portfolio.Tiaa Cref Investment Management boosted its stake in RPTP in the latest quarter, The investment management firm added 18,781 additional shares and now holds a total of 269,356 shares of Raptor Pharmaceutical Corp. which is valued at $1,826,234. Alambic Investment Management added RPTP to its portfolio by purchasing 10,100 company shares during the most recent quarter which is valued at $68,175. Raptor Pharmaceutical Corp. makes up approx 0.02% of Alambic Investment Management’s portfolio.Turner Investments boosted its stake in RPTP in the latest quarter, The investment management firm added 16,430 additional shares and now holds a total of 177,530 shares of Raptor Pharmaceutical Corp. which is valued at $1,223,182. Raptor Pharmaceutical Corp. makes up approx 0.36% of Turner Investments’s portfolio.
Raptor Pharmaceutical Corp. closed down -0.21 points or -2.82% at $7.24 with 5,60,499 shares getting traded on Thursday. Post opening the session at $7.44, the shares hit an intraday low of $7.168 and an intraday high of $7.56 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Raptor Pharmaceutical Corp. reported $-0.16 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.17. The company had revenue of $32.05 million for the quarter, compared to analysts expectations of $28.51 million. The company’s revenue was up 37.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.17 EPS.
Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company’s product PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe PROCYSBI gastro-resistant hard capsules of cysteamine received a marketing authorization from the European Commission (EC) as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Company’s pipeline includes its delayed-release form of cysteamine or RP103 and its oral 4-methylpyrazole or Convivia. Its other product Quinsair is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.